{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:34Z","timestamp":1792202374355,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94679-7","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T03:12:48Z","timestamp":1746155568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon"],"prefix":"10.1038","volume":"15","author":[{"given":"Gabrielly S.","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via A.","family":"Fontenelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda O.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle M.","family":"Mac\u00eado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela C.","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca L.","family":"Abreu Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor I.","family":"Mwangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G. C.","family":"Alecrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus V. G.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Rodrigues-Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C. G.","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisely Cardoso","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"94679_CR1","unstructured":"WHO. World malaria World malaria report 2023 [Internet]. 283. https:\/\/www.wipo.int\/amc\/en\/mediation\/0. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023  (2023)."},{"key":"94679_CR2","first-page":"1","volume":"53","author":"Secretaria de Vigil\u00e2sncia em Sa\u00fade\/Minist\u00e9rio da Saude","year":"2022","unstructured":"Secretaria de Vigil\u00e2sncia em Sa\u00fade\/Minist\u00e9rio da Saude. Panorama epidemiol\u00f3gico Da mal\u00e1ria Em 2021: Buscando O Caminho Para a elimina\u00e7\u00e3o Da mal\u00e1ria no Brasil. Bol. Epidemiol. 53, 1\u201317 (2022).","journal-title":"Bol. Epidemiol\u00f3gico"},{"key":"94679_CR3","doi-asserted-by":"crossref","unstructured":"White, M. T., Shirreff, G., Karl, S., Ghani, A. C. & Mueller, I. Variation in relapse frequency and the transmission potential of plasmodium Vivax malaria. Proc. R. Soc. B Biol. Sci. 283(1827) (2016).","DOI":"10.1098\/rspb.2016.0048"},{"key":"94679_CR4","doi-asserted-by":"publisher","unstructured":"Zanghi, G. & Vaughan, A. M. Plasmodium vivax pre-erythrocytic stages and the latent hypnozoite. Parasitol. Int.  85(August), 102447.  https:\/\/doi.org\/10.1016\/j.parint.2021.102447 (2021).","DOI":"10.1016\/j.parint.2021.102447"},{"key":"94679_CR5","doi-asserted-by":"publisher","unstructured":"Chu, C. S. & White, N. J. Management of relapsing Plasmodium vivax malaria. Expert Rev. Anti Infect. Ther. 14(10), 885\u2013900. https:\/\/doi.org\/10.1080\/14787210.2016.1220304 (2016).","DOI":"10.1080\/14787210.2016.1220304"},{"key":"94679_CR6","doi-asserted-by":"crossref","unstructured":"Pybus, B. S. et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar. J.  11(1), 1 (2012).","DOI":"10.1186\/1475-2875-11-259"},{"issue":"4","key":"94679_CR7","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1128\/AAC.00015-15","volume":"59","author":"BMJ Potter","year":"2015","unstructured":"Potter, B. M. J. et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob. Agents Chemother. 59 (4), 2380\u20132387 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94679_CR8","doi-asserted-by":"crossref","unstructured":"Pybus, B. S. et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar. J.  12(1), 1  (2013).","DOI":"10.1186\/1475-2875-12-212"},{"issue":"6","key":"94679_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","volume":"392","author":"UM Zanger","year":"2008","unstructured":"Zanger, U. M., Turpeinen, M., Klein, K. & Schwab, M. Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal Chem. 392 (6), 1093\u20131108 (2008).","journal-title":"Anal. Bioanal Chem."},{"key":"94679_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119\u2013137 (2006).","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"94679_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 (1), 6\u201313 (2005).","journal-title":"Pharmacogenomics J."},{"key":"94679_CR12","unstructured":"CYP2D6 [Internet]. PharmGKB. https:\/\/www.pharmgkb.org\/gene\/PA128"},{"key":"94679_CR13","doi-asserted-by":"crossref","unstructured":"Marco Bortolato, K. & Chen and JCS. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv Rev.  (2008).","DOI":"10.1016\/j.addr.2008.06.002"},{"key":"94679_CR14","unstructured":"Nishioka, S. A. et al. The Role of the VNTR functional polymorphism of the promoter region of the MAOA gene on psychiatric disorders. Role VNTR Funct. Polymorph Promot. Reg. MAOA Gene Psychiatr. Disord. 38(1), 34\u201342 (2011)."},{"key":"94679_CR15","doi-asserted-by":"crossref","unstructured":"Neri, L. et al. Aggressiveness in Italian children with ADHD: MAOA gene polymorphism involvement. Dis. (Basel Switzerland) 12(4) (2024).","DOI":"10.3390\/diseases12040070"},{"key":"94679_CR16","doi-asserted-by":"publisher","first-page":"101875","DOI":"10.1016\/j.pneurobio.2020.101875","volume":"194","author":"NJ Kolla","year":"2020","unstructured":"Kolla, N. J. & Bortolato, M. The role of monoamine oxidase A in the neurobiology of aggressive, antisocial, and violent behavior: A Tale of mice and men. Prog Neurobiol. 194, 101875 (2020).","journal-title":"Prog Neurobiol."},{"key":"94679_CR17","doi-asserted-by":"crossref","unstructured":"Aklillu, E., Karlsson, S., Zachrisson, O. O., Ozdemir, V. & Agren, H. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet. Genom.  19(4).  https:\/\/journals.lww.com\/jpharmacogenetics\/fulltext\/2009\/04000\/association_of_maoa_gene_functional_promoter.3.aspx (2009).","DOI":"10.1097\/FPC.0b013e328328d4d3"},{"issue":"3","key":"94679_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","volume":"3","author":"C Guillemette","year":"2003","unstructured":"Guillemette, C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3 (3), 136\u2013158 (2003).","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"94679_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.tpj.6500139","volume":"3","author":"M Holthe","year":"2003","unstructured":"Holthe, M. et al. Sequence variations in the UDP - Glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucoronidation in cancer patients. Pharmacogenomics J. 3 (1), 17\u201326 (2003).","journal-title":"Pharmacogenomics J."},{"key":"94679_CR20","unstructured":"Jason, W. et al. Gregory Deye, victor Melendez CFO. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax (2013)."},{"key":"94679_CR21","doi-asserted-by":"publisher","unstructured":"Brasil, L. W. et al. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: A prospective cohort study. Malar. J. 17(1), 1\u20136. https:\/\/doi.org\/10.1186\/s12936-017-2139-7 (2018).","DOI":"10.1186\/s12936-017-2139-7"},{"key":"94679_CR22","first-page":"1","volume":"13","author":"M Chamnanphon","year":"2020","unstructured":"Chamnanphon, M. et al. Pharmacogene variation in Thai plasmodium Vivax relapse patients treated with a combination of primaquine and chloroquine. Pharmgenomics Pers. Med. 13, 1\u201312 (2020).","journal-title":"Pharmgenomics Pers. Med."},{"issue":"1","key":"94679_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1270-1","volume":"15","author":"PS Fasinu","year":"2016","unstructured":"Fasinu, P. S. et al. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes. Malar. J. 15 (1), 1\u201312 (2016).","journal-title":"Malar. J."},{"issue":"2","key":"94679_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13318-013-0139-8","volume":"39","author":"X Jin","year":"2014","unstructured":"Jin, X. et al. An LC-MS based study of the metabolic profile of Primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur. J. Drug Metab. Pharmacokinet. 39 (2), 139\u2013146 (2014).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"94679_CR25","doi-asserted-by":"crossref","unstructured":"Ariffin, N. M., Islahudin, F., Kumolosasi, E. & Makmor-bakry, M. Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers. Parasitol. Res. (2019).","DOI":"10.1007\/s00436-019-06210-3"},{"issue":"11","key":"94679_CR26","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1517\/17425255.2014.964204","volume":"10","author":"A LLerena","year":"2014","unstructured":"LLerena, A. et al. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin. Drug Metab. Toxicol. 10 (11), 1569\u20131583 (2014).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"10","key":"94679_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.pone.0110691","volume":"9","author":"DC Friedrich","year":"2014","unstructured":"Friedrich, D. C. et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One. 9 (10), 5\u201312 (2014).","journal-title":"PLoS One"},{"issue":"5","key":"94679_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02056-19","volume":"64","author":"ACR Silvino","year":"2020","unstructured":"Silvino, A. C. R. et al. Novel insights into plasmodium Vivax therapeutic failure: CYP2D6 activity and time of exposure to malaria modulate the risk of recurrence. Antimicrob. Agents Chemother. 64 (5), 1\u201314 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94679_CR29","doi-asserted-by":"publisher","unstructured":"Park, Y. A., Park, K. H., Yoon, H. Y., Yee, J. & Gwak, H. S. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis. Travel Med. Infect. Dis. 48(April), 102333.  https:\/\/doi.org\/10.1016\/j.tmaid.2022.102333 (2022).","DOI":"10.1016\/j.tmaid.2022.102333"},{"issue":"7","key":"94679_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0160172","volume":"11","author":"ACR Silvino","year":"2016","unstructured":"Silvino, A. C. R. et al. Variation in human cytochrome P-450 drug-metabolism genes: A gateway to the Understanding of plasmodium Vivax relapses. PLoS One 11 (7), 1\u201314 (2016).","journal-title":"PLoS One"},{"issue":"4\u20135","key":"94679_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0940-2993(99)80010-4","volume":"51","author":"L Constantino","year":"1999","unstructured":"Constantino, L. et al. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to Carboxyprimaquine. Exp. Toxicol. Pathol. 51 (4\u20135), 299\u2013303 (1999).","journal-title":"Exp. Toxicol. Pathol."},{"key":"94679_CR32","unstructured":"gnomAD Genome. MAOA rs1137070 [Internet]. PharmGKB.  https:\/\/www.pharmgkb.org\/variant\/PA166170103"},{"key":"94679_CR33","doi-asserted-by":"publisher","unstructured":"Avula, B. et al. Metabolism of primaquine in normal human volunteers: investigation of phase I and phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Malar. J.  17(1), 294. https:\/\/doi.org\/10.1186\/s12936-018-2433-z (2018).","DOI":"10.1186\/s12936-018-2433-z"},{"issue":"2","key":"94679_CR34","first-page":"383","volume":"49","author":"GS Hotamisligil","year":"1991","unstructured":"Hotamisligil, G. S. & Breakefield, X. O. Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 49 (2), 383\u2013392 (1991).","journal-title":"Am. J. Hum. Genet."},{"key":"94679_CR35","doi-asserted-by":"publisher","unstructured":"Popovici, J., Tebben, K., Witkowski, B. & Serre, D. Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters. Int. J. Parasitol. Drugs Drug Resist.  15(January), 36\u201342.   https:\/\/doi.org\/10.1016\/j.ijpddr.2020.12.004 (2021).","DOI":"10.1016\/j.ijpddr.2020.12.004"},{"key":"94679_CR36","doi-asserted-by":"publisher","unstructured":"Pu\u00e7a, M. C. S. D. B. et al. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses. J. Antimicrob. Chemother.  79(8), 1985\u20139. https:\/\/doi.org\/10.1093\/jac\/dkae196  (2024).","DOI":"10.1093\/jac\/dkae196"},{"key":"94679_CR37","unstructured":"gnomAD & Genome UGT2B7 rs28365063 [Internet]. PharmGKB. https:\/\/www.pharmgkb.org\/variant\/PA166156677"},{"issue":"September","key":"94679_CR38","first-page":"1","volume":"60","author":"AGNC Mello","year":"2018","unstructured":"Mello, A. G. N. C. et al. Levels of primaquine and Carboxyprimaquine in patients with malaria Vivax from the Brazilian Amazon basin. Rev. Inst. Med. Trop. Sao Paulo 60 (September), 1\u20136 (2018).","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"4","key":"94679_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1001\/jamanetworkopen.2018.1449","volume":"1","author":"JK Baird","year":"2018","unstructured":"Baird, J. K. et al. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent plasmodium Vivax malaria. JAMA Netw. Open. 1 (4), 4\u201315 (2018).","journal-title":"JAMA Netw. Open."},{"issue":"3","key":"94679_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda, M. V. G. et al. Single-Dose tafenoquine to prevent relapse of plasmodium Vivax malaria. N Engl. J. Med. 380 (3), 215\u2013228 (2019).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"94679_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas, A. et al. Tafenoquine versus primaquine to prevent relapse of plasmodium Vivax malaria. N Engl. J. Med. 380 (3), 229\u2013241 (2019).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"94679_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(24)00074-4","volume":"24","author":"M Brito","year":"2024","unstructured":"Brito, M. et al. Operational effectiveness of tafenoquine and primaquine for the prevention of plasmodium Vivax recurrence in Brazil: a retrospective observational study. Lancet Infect. Dis. 24 (6), 629\u2013638 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"94679_CR43","doi-asserted-by":"publisher","unstructured":"Daher, A. et al. Evaluation of Plasmodium vivax malaria recurrence in Brazil. Malar. J. 18(1):1\u201310. https:\/\/doi.org\/10.1186\/s12936-019-2644-y (2019).","DOI":"10.1186\/s12936-019-2644-y"},{"key":"94679_CR44","unstructured":"Brasil Minist\u00e9rio da Sa\u00fade. Guia de tratamento da mal\u00e1ria no Brasil [Internet].   https:\/\/portalarquivos2.saude.gov.br\/images\/pdf\/2020\/janeiro\/29\/af-guia-tratamento-malaria-28jan20-isbn.pdf (2021)."},{"key":"94679_CR45","unstructured":"PharmGKB. CYP2D6 Allele Definition Table [Internet]. PharmGKB. https:\/\/www.pharmgkb.org\/page\/cyp2d6RefMaterials"},{"issue":"1","key":"94679_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0378-4347(95)00357-6","volume":"675","author":"VK Dua","year":"1996","unstructured":"Dua, V. K., Kar, P. K., Sarin, R. & Sharma, V. P. High-performance liquid chromatographic determination of primaquine and Carboxyprimaquine concentrations in plasma and blood cells in plasmodium Vivax malaria cases following chronic dosage with primaquine. J. Chromatogr. B Biomed. Appl. 675 (1), 93\u201398 (1996).","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"94679_CR47","unstructured":"Pharmacogene Variation Consortium (PharmVar) [Internet].  https:\/\/www.pharmvar.org\/gene\/CYP2D6 (2023)."},{"issue":"1","key":"94679_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle, K. E. et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin. Transl Sci. 13 (1), 116\u2013124 (2020).","journal-title":"Clin. Transl Sci."},{"issue":"1","key":"94679_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T. & Steven Leeder, J. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19 (1), 69\u201376 (2017).","journal-title":"Genet. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94679-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94679-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94679-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T03:12:59Z","timestamp":1746155579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94679-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94679"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94679-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15330"}}